| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
182.32(B) |
| Last
Volume: |
9,644,407 |
Avg
Vol: |
2,722,478 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
14,213 |
23,771 |
45,603 |
| Total Sell Value |
$662,802 |
$3,963,214 |
$6,471,520 |
$11,852,673 |
| Total People Sold |
1 |
2 |
3 |
6 |
| Total Sell Transactions |
1 |
3 |
4 |
10 |
| End Date |
2024-02-06 |
2023-11-05 |
2023-05-07 |
2022-05-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Louie Linda H. |
VP, Finance & CAO |
• • – |
2022-04-27 |
4 |
D |
$249.87 |
$4,248 |
D/D |
(17) |
9,004 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2022-04-27 |
4 |
D |
$249.87 |
$6,996 |
D/D |
(28) |
6,828 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2022-04-27 |
4 |
D |
$249.87 |
$636,419 |
D/D |
(2,547) |
610,769 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2022-04-27 |
4 |
D |
$249.87 |
$45,976 |
D/D |
(184) |
47,755 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2022-04-27 |
4 |
D |
$249.87 |
$14,992 |
D/D |
(60) |
14,329 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$1,030,708 |
D/D |
(4,370) |
55,920 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$82,551 |
D/D |
(350) |
14,389 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$4,123,069 |
D/D |
(17,481) |
613,316 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$75,947 |
D/D |
(322) |
6,856 |
|
- |
|
| Gordon Murdo |
EVP Global Commercial Ops |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$1,178,121 |
D/D |
(4,995) |
44,865 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$824,567 |
D/D |
(3,496) |
49,195 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$77,126 |
D/D |
(327) |
5,516 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$25,473 |
D/D |
(108) |
9,021 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2022-03-18 |
4 |
D |
$235.86 |
$1,178,121 |
D/D |
(4,995) |
47,939 |
|
- |
|
| Miller Derek |
SVP, Human ResourcesOfficer |
• – – |
2022-03-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,843 |
|
7% |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,001 |
14,638 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
436 |
9,104 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,740 |
60,119 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,989 |
52,714 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
34,964 |
630,141 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,992 |
52,487 |
|
- |
|
| Gordon Murdo |
EVP Global Commercial Ops |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,989 |
49,682 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
7,139 |
|
- |
|
| Johnston Lori A |
EVP, HR |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,495 |
40,881 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,104 |
6,185 |
|
- |
|
2168 Records found
|
|
Page 9 of 87 |
|
|
32.90 (11.82%) 
